-
Product Insights
Pruritus – Drugs In Development, 2023
Global Markets Direct’s, ‘Pruritus - Drugs In Development, 2023’, provides an overview of the Pruritus pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pruritus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Allergic Rhinitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Allergic Rhinitis - Drugs In Development, 2023’, provides an overview of the Allergic Rhinitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nivolumab in Germ Cell Tumors
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in Germ Cell Tumors report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nivolumab in Germ Cell Tumors Drug Details: Nivolumab (Opdivo, Opdyta)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – B-244 in Acne Vulgaris
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - B-244 in Acne Vulgaris report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.B-244 in Acne Vulgaris Drug Details:B-244 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – B-244 in Pruritus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - B-244 in Pruritus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.B-244 in Pruritus Drug Details:B-244 is under development for the treatment of acne vulgaris,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – B-244 in Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - B-244 in Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.B-244 in Hypertension Drug Details:B-244 is under development for the treatment of acne vulgaris,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – B-244 in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - B-244 in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.B-244 in Atopic Dermatitis (Atopic Eczema) Drug Details:B-244 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nedisertib in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nedisertib in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nedisertib in Non-Small Cell Lung Cancer Drug Details: Nedisertib...
-
Product Insights
Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. The Hypertension pipeline market research report provides comprehensive information on the therapeutics under development for Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases....